Janux Therapeutics (NASDAQ:JANX) Releases Quarterly Earnings Results, Misses Estimates By $0.18 EPS

Janux Therapeutics (NASDAQ:JANX) posted its earnings results on Wednesday. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18), Briefing.com reports. The business had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.50 million. Janux Therapeutics had a negative return on equity of 10.95% and a negative net margin of 463.91%. The company’s revenue for the quarter was down 82.6% compared to the same quarter last year.

Janux Therapeutics Price Performance

Shares of NASDAQ:JANX traded down $0.29 during trading on Friday, hitting $53.92. The company’s stock had a trading volume of 844,979 shares, compared to its average volume of 684,814. The firm has a market cap of $2.81 billion, a price-to-earnings ratio of -46.09 and a beta of 3.52. The company has a 50-day moving average of $49.02 and a 200-day moving average of $46.39. Janux Therapeutics has a 12 month low of $5.65 and a 12 month high of $65.60.

Insider Buying and Selling at Janux Therapeutics

In other news, major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $42.33, for a total value of $92,364.06. Following the completion of the sale, the insider now directly owns 7,000 shares of the company’s stock, valued at $296,310. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Janux Therapeutics news, CEO David Alan Campbell sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $53.54, for a total transaction of $1,338,500.00. Following the completion of the transaction, the chief executive officer now owns 282,054 shares in the company, valued at $15,101,171.16. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $42.33, for a total value of $92,364.06. Following the transaction, the insider now owns 7,000 shares of the company’s stock, valued at $296,310. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 420,610 shares of company stock valued at $19,288,666. Insiders own 29.40% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on JANX. HC Wainwright reaffirmed a “buy” rating and set a $63.00 price objective on shares of Janux Therapeutics in a research note on Thursday. Cantor Fitzgerald reiterated an “overweight” rating and set a $100.00 price target on shares of Janux Therapeutics in a report on Thursday. Scotiabank lowered their price target on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a report on Friday, August 9th. Stifel Nicolaus initiated coverage on shares of Janux Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $70.00 price objective on the stock. Finally, UBS Group initiated coverage on shares of Janux Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $69.00 target price on the stock. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $66.44.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.